YibeissineCAS# 143502-51-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 143502-51-6 | SDF | Download SDF |
| PubChem ID | 3083381.0 | Appearance | Powder |
| Formula | C27H41NO4 | M.Wt | 443.62 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3S,3'R,3'aS,4aS,6'S,6aS,6bS,7'aR,9R,11R,11aS,11bR)-3,11-dihydroxy-3',6',10,11b-tetramethylspiro[1,2,3,4,4a,6,6a,6b,7,8,11,11a-dodecahydrobenzo[a]fluorene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-5-one | ||
| SMILES | CC1CC2C(C(C3(O2)CCC4C5CC(=O)C6CC(CCC6(C5C(C4=C3C)O)C)O)C)NC1 | ||
| Standard InChIKey | NURPXYQPDMVKOY-RUKZUWONSA-N | ||
| Standard InChI | InChI=1S/C27H41NO4/c1-13-9-21-24(28-12-13)15(3)27(32-21)8-6-17-18-11-20(30)19-10-16(29)5-7-26(19,4)23(18)25(31)22(17)14(27)2/h13,15-19,21,23-25,28-29,31H,5-12H2,1-4H3/t13-,15+,16-,17-,18-,19+,21+,23+,24-,25-,26-,27-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Yibeissine Dilution Calculator
Yibeissine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2542 mL | 11.2709 mL | 22.5418 mL | 45.0836 mL | 56.3545 mL |
| 5 mM | 0.4508 mL | 2.2542 mL | 4.5084 mL | 9.0167 mL | 11.2709 mL |
| 10 mM | 0.2254 mL | 1.1271 mL | 2.2542 mL | 4.5084 mL | 5.6355 mL |
| 50 mM | 0.0451 mL | 0.2254 mL | 0.4508 mL | 0.9017 mL | 1.1271 mL |
| 100 mM | 0.0225 mL | 0.1127 mL | 0.2254 mL | 0.4508 mL | 0.5635 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3-[[6-Deoxy-2-O-[6-O-[3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-β-D-glucopyranosyl]-α-L-mannopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-7-(β-D-glucopyranosyloxy)-5-hydroxy-4H-1-benzopyran-4-one
Catalog No.:BCX0788
CAS No.:1575672-58-0
- Chrysotoxine
Catalog No.:BCX0787
CAS No.:156951-82-5
- Verbascose
Catalog No.:BCX0786
CAS No.:546-62-3
- Myricetin 3'-methyl-3-O-rutinoside
Catalog No.:BCX0785
CAS No.:55481-90-8
- Choerospondin
Catalog No.:BCX0784
CAS No.:81202-36-0
- 3-O-p-Coumaroylquinic acid
Catalog No.:BCX0783
CAS No.:5746-55-4
- Bixin
Catalog No.:BCX0782
CAS No.:6983-79-5
- Frangufoline
Catalog No.:BCX0781
CAS No.:19526-09-1
- Malonic acid
Catalog No.:BCX0780
CAS No.:90844-16-9
- Isogermafurenolide
Catalog No.:BCX0779
CAS No.:20267-89-4
- Nardoguaianone J
Catalog No.:BCX0778
CAS No.:443128-64-1
- Verrucosin
Catalog No.:BCX0777
CAS No.:83198-63-4
- 6-hydroxyl kaempherol-3,6-O-diglucosyl-7-O-Glucuronic acid
Catalog No.:BCX0790
CAS No.:307950-53-4
- N-noratherosperminine
Catalog No.:BCX0791
CAS No.:74606-53-4
- Nor-rubrofusarin-6-O-β-D-gentiobioside
Catalog No.:BCX0792
CAS No.:245724-08-7
- 7,4′-Dihydroxyhomoisoflavane
Catalog No.:BCX0793
CAS No.:148462-00-4
- O-Cymen-5-ol
Catalog No.:BCX0794
CAS No.:39660-61-2
- Magnoloside B
Catalog No.:BCX0795
CAS No.:116872-05-0
- (-)-Epipodophyllotoxin
Catalog No.:BCX0796
CAS No.:4375-07-9
- Kanzonol D
Catalog No.:BCX0797
CAS No.:155233-20-8
- 17-Hydroxygracillin
Catalog No.:BCX0798
CAS No.:90308-85-3
- Pterin-6-carboxylic acid
Catalog No.:BCX0799
CAS No.:948-60-7
- Prosaikogenin G
Catalog No.:BCX0800
CAS No.:99365-23-8
- Harmalan
Catalog No.:BCX0801
CAS No.:525-41-7
Revealing active components and action mechanism of Fritillariae Bulbus against non-small cell lung cancer through spectrum-effect relationship and proteomics.[Pubmed:36587416]
Phytomedicine. 2023 Feb;110:154635.
BACKGROUND: Fritillariae Bulbus (FB) is widely used as a traditional medicine for the treatment of lung meridian diseases. It has been proved that FB has good anti-non-small cell lung cancer (NSCLC) activity. However, the active components and potential mechanism are still not clear. PURPOSE: To reveal the bioactive components of FB against NSCLC and potential mechanism through spectrum-effect relationship and proteomics. METHOD: First, the FB extract was chemically profiled by UHPLC-QTOF-MS and the inhibitory effect of FB extract on A549 cell viability was evaluated by Cell Counting Kit-8 assay. Second, orthogonal-partial least squares-regression analysis was applied to screen potential active compounds through correlating the chemical profile with corresponding inhibitory effect. Third, the anti-NSCLC activities of potential active components were further investigated in terms of cell proliferation, cell cycle and cell apoptosis in vitro and tumor growth in vivo. Finally, proteomics was utilized to reveal the underlying anti-NSCLC mechanism. RESULTS: Six potential active components including verticine, verticinone, zhebeirine, ebeiedinone, Yibeissine and peimisine were screened out by spectrum-effect relationship. Among them, zhebeirine showed higher inhibitory effect on A549 cell viability with IC(50) value of 36.93 muM and dosage-dependent inhibition of A549 xenograft tumor growth in nude mice. Proteomics and western blotting assays indicated that zhebeirine could arrest cell cycle by down-regulating the expressions of CDK1, CDK2, Cyclin A2, Cyclin B2 and inhibiting the phosphorylation of p53. Moreover, the proteins participating in p53 signaling pathway including PCNA, 14-3-3sigma, CHEK1 were significantly decreased, which suggested that zhebeirine affected cell cycle progression through p53 signaling pathway. CONCLUSION: This study not only provides scientific evidence to support the clinical application of FB against NSCLC, but also demonstrates that zhebeirine is a promising anti-NSCLC lead compound deserving further studies.
Water Extract of Fritillariae thunbergii Bulbus Inhibits RANKL-Mediated Osteoclastogenesis and Ovariectomy-Induced Trabecular Bone Loss.[Pubmed:35011398]
Molecules. 2021 Dec 28;27(1):169.
Fritillariae thunbergii bulbus has been widely used to treat symptoms of coughs and airway congestion in the chest due to pathological colds and damp phlegm in traditional Chinese medicine. Despite its long history of traditional use, its pharmacological activities on osteoclastogenesis and osteoporosis have not been evaluated. This study investigated the effects of the water extract of Fritillariae thunbergii bulbus (WEFT) on osteoclast differentiation in bone marrow-derived macrophage cells and on ovariectomy (OVX)-induced osteoporosis in mice. We found that WEFT significantly inhibited osteoclastogenesis by downregulating the receptor activator of the NF-kappaB ligand (RANKL) signaling-induced nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) expression. In an OVX-induced osteoporosis model, WEFT significantly prevented the OVX-induced trabecular loss of femurs, accompanied by a reduction in fat accumulation in the bone marrow and liver. In addition, WEFT significantly prevented weight gain and gonadal fat gain without recovering uterine atrophy. Using ultrahigh-performance liquid chromatography-tandem mass spectrometry, seven alkaloids (peimisine glucoside, Yibeissine, peiminoside, sipeimine-glucoside, peimisine, peimine, and peiminine) were identified in WEFT. The results of this study suggest that WEFT can be a potential pharmacological candidate to reduce menopausal osteoporosis and menopause-related symptoms, such as fat accumulation.
[Isolation and identification of yibeissine].[Pubmed:1414366]
Yao Xue Xue Bao. 1992;27(2):121-4.
A new steroidal alkaloid, Yibeissine (II), with a know alkaloid (I) was isolated from the bulb of Fritillaria pallioiflora Schrenk by column chromatographic techniques. Their structures have been determined based on spectral and chemical data.
